enGene (NASDAQ:ENGN) Receives “Market Outperform” Rating from JMP Securities

enGene (NASDAQ:ENGN)‘s stock had its “market outperform” rating reissued by equities research analysts at JMP Securities in a report released on Monday,Benzinga reports. They presently have a $18.00 target price on the stock. JMP Securities’ price objective suggests a potential upside of 208.75% from the company’s current price.

A number of other equities analysts have also commented on ENGN. HC Wainwright started coverage on shares of enGene in a research report on Monday. They issued a “buy” rating and a $25.00 price target on the stock. Morgan Stanley restated an “overweight” rating and set a $40.00 price target on shares of enGene in a research report on Wednesday, September 11th. Raymond James began coverage on enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price objective for the company. Oppenheimer restated an “outperform” rating and set a $30.00 target price on shares of enGene in a report on Tuesday, September 24th. Finally, Citizens Jmp raised enGene to a “strong-buy” rating in a report on Monday, November 18th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, enGene presently has an average rating of “Buy” and an average target price of $29.78.

enGene Stock Performance

NASDAQ:ENGN opened at $5.83 on Monday. enGene has a 12-month low of $4.42 and a 12-month high of $18.40. The firm has a market capitalization of $257.78 million, a PE ratio of -10.05 and a beta of -0.78. The firm has a 50-day moving average price of $8.13 and a 200 day moving average price of $7.80. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last posted its earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06. Research analysts anticipate that enGene will post -1.52 earnings per share for the current fiscal year.

Insider Activity

In other enGene news, CEO Ronald Harold Wilfred Cooper bought 10,000 shares of the stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $5.70 per share, with a total value of $57,000.00. Following the acquisition, the chief executive officer now owns 10,000 shares of the company’s stock, valued at approximately $57,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Growth Opportunities F. Forbion purchased 341,332 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was bought at an average cost of $6.34 per share, for a total transaction of $2,164,044.88. Following the purchase, the insider now owns 2,400,791 shares in the company, valued at $15,221,014.94. This trade represents a 16.57 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 420,965 shares of company stock valued at $2,651,103. 13.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On enGene

Institutional investors have recently bought and sold shares of the company. Wolverine Asset Management LLC acquired a new stake in shares of enGene in the third quarter valued at approximately $37,000. Point72 Asset Management L.P. lifted its position in enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after buying an additional 619,100 shares in the last quarter. SR One Capital Management LP acquired a new position in shares of enGene during the 2nd quarter worth about $4,715,000. Franklin Resources Inc. increased its position in shares of enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after acquiring an additional 389,918 shares during the last quarter. Finally, Logos Global Management LP raised its holdings in enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after acquiring an additional 400,000 shares in the last quarter. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.